This HTML5 document contains 45 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/drugbank/drug/DB04957/identifier/chemspider/
n15http://linked.opendata.cz/resource/drugbank/drug/DB04957/identifier/wikipedia/
n8http://bio2rdf.org/drugbank:
n9http://linked.opendata.cz/resource/drugbank/drug/DB04957/identifier/kegg-compound/
n6http://linked.opendata.cz/resource/drugbank/drug/DB04957/identifier/bindingdb/
admshttp://www.w3.org/ns/adms#
n10http://linked.opendata.cz/resource/drugbank/drug/DB04957/identifier/pubchem-compound/
n14http://linked.opendata.cz/resource/drugbank/drug/DB04957/identifier/pubchem-substance/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n12http://linked.opendata.cz/resource/drugbank/drug/DB04957/identifier/drugbank/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB04957
rdf:type
n3:Drug
n3:description
Azimilide is an investigational class III anti-arrhythmic drug that blocks fast and slow components of the delayed rectifier cardiac potassium channels. It is not approved for use in any country, but is currently in clinical trials in the United States.
n3:generalReferences
# Schmitt H, Cabo C, Coromilas JC, Wit AL: Effects of azimilide, a new class III antiarrhythmic drug, on reentrant circuits causing ventricular tachycardia and fibrillation in a canine model of myocardial infarction. J Cardiovasc Electrophysiol. 2001 Sep;12(9):1025-33. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11573692 # Abrol R, Page RL: Azimilide dihydrochloride: a new class III anti-arrhythmic agent. Expert Opin Investig Drugs. 2000 Nov;9(11):2705-15. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11060832 # Tran HT: Azimilide dihydrochloride: a unique class III antiarrhythmic agent. Heart Dis. 1999 May-Jun;1(2):114-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11720612 # Toothaker RD, Corey AE, Valentine SN, Agnew JR, Parekh N, Moehrke W, Thompson GA, Powell JH: Influence of coadministration on the pharmacokinetics of azimilide dihydrochloride and digoxin. J Clin Pharmacol. 2005 Jul;45(7):773-80. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15951467 # Riley P, Figary PC, Entwisle JR, Roe AL, Thompson GA, Ohashi R, Ohashi N, Moorehead TJ: The metabolic profile of azimilide in man: in vivo and in vitro evaluations. J Pharm Sci. 2005 Sep;94(9):2084-95. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16052551
n3:group
investigational
n3:indication
Investigated for use/treatment in arrhythmia and atrial fibrillation.
owl:sameAs
n8:DB04957
dcterms:title
Azimilide
adms:identifier
n6:50117913 n9:C13777 n10:9571004 n11:7845470 n12:DB04957 n14:14833668 n15:Azimilide
n3:mechanismOfAction
The mechanism of action of azimilide is to block both the slowly conducting (I(Ks)) and rapidly conducting (I(Kr)) rectifier potassium currents in cardiac cells. This differs from other class III agents that block I(Kr) exclusively or in combination with sodium, calcium, or transient outward (I(to)) potassium current channels. It also has blocking effects on sodium (I(Na)) and calcium currents (I(CaL)). Its effects on reentrant circuits in infarct border zones causing ventricular tachyarrhythmias are unknown.
n3:IUPAC-Name
n4:271B612C-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B6132-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B6131-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B612E-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B612F-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B6130-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B612A-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B612B-363D-11E5-9242-09173F13E4C5 n4:271B6128-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B6129-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B6138-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B6139-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B6133-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B6134-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B6136-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B6135-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B6137-363D-11E5-9242-09173F13E4C5
n3:absorption
Excellent oral absorption.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
149908-53-2
n3:category
n3:Bioavailability
n4:271B613E-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B6140-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B6141-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B613D-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B613C-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B613F-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B612D-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B613A-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B613B-363D-11E5-9242-09173F13E4C5